Summit Therapeutics establishes up to $380M at-the-market equity offering program

Filed July 23, 2026 · Period ending July 23, 2026 · ~1 min read

Key Changes

• high

  Summit entered into a distribution agreement with J.P. Morgan Securities to sell up to $380M of common stock over time through an at-the-market program, providing flexible capital access with no obligation to sell.

  Item 1.01 verify on EDGAR →
• medium

  The company will pay J.P. Morgan a commission of up to 3.0% of gross sales proceeds for shares sold under the program, with full discretion over timing, pricing, and volume of any sales.

  Item 1.01 verify on EDGAR →
• low

  The ATM program operates under Summit's shelf registration statement filed June 9, 2026, with a prospectus supplement filed July 23, 2026 to enable the offering.

  Item 1.01 verify on EDGAR →